Jura Bio utilizes AI-driven drug discovery and development, leveraging extensive biological datasets and optimized iterative design to create therapeutics for autoimmune disorders. The company aims to translate the successes of CAR-T therapies into effective treatments for these complex conditions.
Funding
$16.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Developing effective treatments for autoimmune disorders is challenging due to the complexity of these conditions and the limitations of traditional drug discovery methods. Existing approaches often struggle to identify and validate promising therapeutic targets, resulting in lengthy development timelines and high failure rates.
Solution
Jura Bio employs an AI-driven drug discovery and development platform to create therapeutics for autoimmune disorders. The Vista Platform combines machine inference with extensive, high-quality biological datasets and autonomously optimized iterative design. This approach aims to accelerate the identification of potential drug candidates and improve the efficiency of the development process for genomic medicine.
Target Audience
The primary audience includes pharmaceutical companies and research institutions focused on developing novel therapeutics for autoimmune disorders.
Features
- AI-native drug discovery platform leveraging machine inference
- Access to a large, continuously refreshed biological data lake
- Clinically-informed generative models for target identification
- Autonomously optimized iterative design for drug development